Name of leader and affiliation: Jorge S. Villacian, Senior Medical Director, Janssen Research & Development, Belgium
Role in RAPP-ID:
The Project Coordinator role is taken by Dr. Jorge Villacian who provides leadership and guidance to the consortium in collaboration with the Academic Coordinator and lead WP8 for managing the Project. In the scientific role, Janssen Research & Development contributes in the description of the characteristics/profile/pathogens during WP1, also with design and target selections during WP 2 where they also provide well characterised clinical isolates of TB and bacterial pathogens. For WP 3 and 4 they provide expertise in sample processing and detection technologies. For WP 5 bacterial/mycobacterial isolates will be provided and for WP7 expertise in clinical validation and samples will be provided. In addition the laboratory facilities at the main research site in Beerse will be provided for use in the different work packages.
J&J as a research-based biotechnology company, applies the most advanced technologies in molecular biology, virology, genomics, robotics and electronic data processing to improve the diagnosis and management of infectious diseases and to reach its mission in providing innovative therapeutic solutions in the field of infectious diseases. The company’s BSL3 lab is the biggest of its kind in Europe. Janssen Research & Development is uniquely positioned to play a pivotal role in bringing novel technologies in infectious diseases that can be integrated in a therapeutic solution for infectious diseases worldwide. In addition, the company is actively involved in multiple European research projects including FP7 grants and government funded private-academic consortia (ART-A- Netherlands).
Dr. Jorge Villacian holds an MD degree from Universidad Anahuac in Mexico and is a Board Certified specialist in Internal Medicine (Mount Sinai Medical Center, Miami) and Infectious Diseases (Mayo Clinic, Rochester, Minnesota). He has extensive clinical experience in Public Health and Infectious Diseases including work in academic centers in the US and Singapore. In previous positions at Boeringer Ingelheim Pharmaceuticals he conducted the pivotal registrational trials for tipranavir in the treatment of HIV and since joining Tibotec-Virco he directs the Medical and Clinical Virology departments. He has authored multiple journal papers, presented at multiple international conferences and symposia and written book chapters in various topics in infectious diseases.
Dr. Lieven Stuyver received his PhD in Molecular Biology from the University of Antwerp in 1992.
Dr. Anil Koul has a PhD in Molecular Biology from the Max Planck Institute.